497 related articles for article (PubMed ID: 17628445)
1. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
2. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani.
Bories C; Cojean S; Huteau F; Loiseau PM
Biomed Pharmacother; 2008 Mar; 62(3):164-7. PubMed ID: 18249083
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
4. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
5. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance.
Pérez-Victoria FJ; Gamarro F; Ouellette M; Castanys S
J Biol Chem; 2003 Dec; 278(50):49965-71. PubMed ID: 14514670
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
Pérez-Victoria FJ; Sánchez-Cañete MP; Seifert K; Croft SL; Sundar S; Castanys S; Gamarro F
Drug Resist Updat; 2006; 9(1-2):26-39. PubMed ID: 16814199
[TBL] [Abstract][Full Text] [Related]
7. Leishmanicidal activity of edelfosine, miltefosine and ilmofosine.
Azzouz S; Maache M; Garcia RG; Osuna A
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):60-5. PubMed ID: 15667597
[TBL] [Abstract][Full Text] [Related]
8. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction.
Verma NK; Singh G; Dey CS
Exp Parasitol; 2007 May; 116(1):1-13. PubMed ID: 17161839
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
10. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites.
Pérez-Victoria FJ; Sánchez-Cañete MP; Castanys S; Gamarro F
J Biol Chem; 2006 Aug; 281(33):23766-75. PubMed ID: 16785229
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
12. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Escobar P; Yardley V; Croft SL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
[TBL] [Abstract][Full Text] [Related]
13. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
[TBL] [Abstract][Full Text] [Related]
14. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
[TBL] [Abstract][Full Text] [Related]
15. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Mishra J; Singh S
Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
[TBL] [Abstract][Full Text] [Related]
16. In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.
Shaw CD; Lonchamp J; Downing T; Imamura H; Freeman TM; Cotton JA; Sanders M; Blackburn G; Dujardin JC; Rijal S; Khanal B; Illingworth CJ; Coombs GH; Carter KC
Mol Microbiol; 2016 Mar; 99(6):1134-48. PubMed ID: 26713880
[TBL] [Abstract][Full Text] [Related]
17. Aspects of the cytological activity of edelfosine, miltefosine, and ilmofosine in Leishmania donovani.
Azzouz S; Maache M; Dos Santos MF; Sarciron ME; Petavy AF; Osuna A
J Parasitol; 2006 Oct; 92(5):877-83. PubMed ID: 17152926
[TBL] [Abstract][Full Text] [Related]
18. Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening.
Singh N; Gupta R; Jaiswal AK; Sundar S; Dube A
J Antimicrob Chemother; 2009 Aug; 64(2):370-4. PubMed ID: 19525291
[TBL] [Abstract][Full Text] [Related]
19. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.
Rakotomanga M; Blanc S; Gaudin K; Chaminade P; Loiseau PM
Antimicrob Agents Chemother; 2007 Apr; 51(4):1425-30. PubMed ID: 17242145
[TBL] [Abstract][Full Text] [Related]
20. Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.
Mondelaers A; Sanchez-Cañete MP; Hendrickx S; Eberhardt E; Garcia-Hernandez R; Lachaud L; Cotton J; Sanders M; Cuypers B; Imamura H; Dujardin JC; Delputte P; Cos P; Caljon G; Gamarro F; Castanys S; Maes L
PLoS One; 2016; 11(4):e0154101. PubMed ID: 27123924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
